8th Annual MarketsandMarkets

Next-Gen Immuno-Oncology Conference

07th - 8th March 2024

London, UK

Leading the Immunotherapy Revolution: Pioneering Advances in Immuno-Oncology

Welcome to the 8th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference, a premier event dedicated to advancing the field of immuno-oncology. Join us on 07th - 8th March 2024 in London, UK, where leading experts, researchers, and industry professionals will gather to shape the future of cancer treatment.

As a prominent Immuno-Oncology Conference, this event offers a unique platform to explore the latest advancements, breakthroughs, and innovations in the field. From antibodies and cellular therapies to immune-checkpoint research, our comprehensive program covers a wide range of topics, ensuring a holistic understanding of the dynamic landscape of immuno-oncology.

Engage in interactive sessions, insightful panel discussions, and thought-provoking keynote speeches delivered by renowned speakers. Contribute to interactive roundtables, where you can deliberate on key topics that are most relevant to your field. Exchange knowledge, network with peers, and foster collaborations with experts from around the world, as we collectively strive to drive progress and inspire hope in the fight against cancer.

CO-LOCATED CONFERENCES

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

SPEAKERS

Henning Lauterbach

Henning Lauterbach

Vice President, Preclinical & Translational Research, HOOKIPA Pharma Inc.

Ali Roghanian

Ali Roghanian

Assistant Professor, Cancer Immunology, University of Southampton, UK

Eike Staub

Eike Staub

Head, Oncology Bioinformatics, Merck Healthcare, Germany

Jonathan Fisher

Jonathan Fisher

T-Cell Immunotherapy, Group Leader, University College London

John Maher

John Maher

Scientific Founder and Chief Scientific Officer, Leucid Bio

Sophia Karagiannis

Sophia Karagiannis

Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK

Dr. Sebastian Lickert

Dr. Sebastian Lickert

Group Lead, ETH Z├╝rich

Lindy Durrant

Lindy Durrant

Professor, Cancer Immunotherapy, University of Nottingham, UK

Farzin Farzaneh

Farzin Farzaneh

CSO, ViroCell Biologics Ltd

Georges Rawadi

Georges Rawadi

CEO, Celyad Oncology

Andrew Pierce

Andrew Pierce

Vice President, Translational Biology, Crescendo Biologics

Stephen Beers

Stephen Beers

Professor, Immunology and Immunotherapy, University of Southampton

Elizabeth Sheppard

Elizabeth Sheppard

Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca

Daniela Kleine-Kohlbrecher

Daniela Kleine-Kohlbrecher

Senior Project Manager Immune Oncology, Evaxion Biotech

Louis Boon

Louis Boon

CSO , JJP Biologics

Valerie Balme

Valerie Balme

Associate Director, Business Development, Veracyte

Ana Hu

Ana Hu

Director, Strategy Business Development, Sanyou Biopharmaceuticals

Senior Representative Volition

Senior Representative Volition

,

Senior Representative Canopy Biosciences

Senior Representative Canopy Biosciences

Senior Representative Canopy Biosciences,

Senior Representative ANGLE plc

Senior Representative ANGLE plc

Senior Representative ANGLE plc,

Konstantin Petropoulos

Konstantin Petropoulos

Chief Business Officer, Secarna Pharmaceuticals

ENQUIRE NOW

SPONSORS

Volition
Sanyou Bio
Veracyte
EpigenDx
Canopy Biosciences - UK
Angle Plc
Novogene

PARTNERS

LOCATION

Venue

London, UK

PAST EVENT GALLERY